Immune checkpoint inhibitor response in mismatch repair-deficient colorectal cancer and other solid tumors: is it truly disease-agnostic?
- 1 December 2020
- journal article
- editorial
- Published by Taylor & Francis Ltd in Colorectal Cancer
- Vol. 9 (4), CRC29
- https://doi.org/10.2217/crc-2020-0020
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Nivolumab Is Effective in Mismatch Repair–Deficient Noncolorectal Cancers: Results From Arm Z1D—A Subprotocol of the NCI-MATCH (EAY131) StudyJournal of Clinical Oncology, 2020
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 StudyJournal of Clinical Oncology, 2020
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeScience, 2017
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 studyThe Lancet Oncology, 2017
- Durable complete response to nivolumab in a patient with HIV and metastatic non-small cell lung cancerJournal of Thoracic Disease, 2017
- Mismatch repair and homeologous recombinationDNA Repair, 2016
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyThe New England Journal of Medicine, 2015
- Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutationsLaboratory Investigation, 2009
- DNA-replication fidelity, mismatch repair and genome instability in cancer cellsPublished by Springer Science and Business Media LLC ,1996
- Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instabilityNature Genetics, 1995